NCT03724890: Study of Avelumab-M3814 Combinations

NCT03724890
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor, Immunotherapy, Therapeutic Antibody, Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with evidence of untreated active central nervous system (CNS) metastases- see trial for details
https://ClinicalTrials.gov/show/NCT03724890

Comments are closed.

Up ↑